Maravai LifeSciences
HQ US50% share
Parent of TriLink BioTechnologies; dominant supplier of GMP modified nucleotides (m1Ψ-UTP) and the CleanCap 5-prime cap analog for mRNA.
pharmaceutical · input
N1-Methylpseudouridine (m1Ψ-UTP) — mRNA Immune Evasion
N1-methylpseudouridine (m1Ψ, m1Psi) is a chemically modified uridine nucleotide that replaces standard uridine in therapeutic mRNA transcripts. The substitution prevents the mRNA from activating innate immune Toll-like receptors (TLR3, TLR7, TLR8) — which would otherwise destroy the mRNA before it can translate its protein. This modification, developed by Karikó and Weissman (2023 Nobel Prize in Medicine), is the fundamental innovation enabling safe mRNA therapeutics. Every approved mRNA vaccine (Pfizer Comirnaty, Moderna Spikevax) and emerging mRNA drug uses m1Ψ in place of uridine. Global suppliers: TriLink BioTechnologies (Maravai), Sigma-Aldrich/Merck KGaA, Hongene Biotech (China), and a few others. The mRNA therapeutic pipeline (cancer vaccines, RSV, influenza, rare diseases) depends critically on m1Ψ supply.
0
Source countries
4
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on n1-methylpseudouridine (m1ψ-utp) — mrna immune evasion somewhere upstream in their supply chain.
Who makes it
Supplier companies
4 companies produce n1-methylpseudouridine (m1ψ-utp) — mrna immune evasion.
Hongene Biotech
HQ CN30% share
Chinese maker of modified nucleotides and oligonucleotide building blocks (incl. m1Ψ).
TriLink BioTechnologies
HQ US30% share
San Diego-based mRNA capping reagent company (subsidiary of Maravai LifeSciences, MRVI); inventor of CleanCap co-transcriptional capping technology; near-monopoly during COVID-19 vaccine era with 350+ preclinical/clinical programs using CleanCap; revenue peaked at $883M (2022), fell to $259M (2024) after COVID demand collapse
Merck KGaA (MilliporeSigma in US)(MRK)
HQ DE
German multinational producing the Hi-Flow Plus nitrocellulose membrane — one of the two industry-standard LFA membranes globally. Received a €121M US DoD/HHS contract to build the first US lateral flow membrane facility in Sheboygan, WI (2022) to reduce concentration risk in Cork, Ireland.